Understanding the ever-changing incidence of thyroid cancer
- PMID: 32895503
- PMCID: PMC7476643
- DOI: 10.1038/s41574-020-00414-9
Understanding the ever-changing incidence of thyroid cancer
Abstract
This Comment article provides a behind-the-scenes perspective and update of our 2016 Review, which discussed possible factors contributing to thyroid cancer incidence trends worldwide. We also highlight promising research directions that are improving the understanding of thyroid cancer aetiology.
Conflict of interest statement
J.A.S. is a member of the Data Monitoring Committee of the Medullary Thyroid Cancer Consortium Registry supported by GlaxoSmithKline, Novo Nordisk, AstraZeneca and Eli Lilly. J.A.S. receives institutional research funding from Exelixis and Eli Lilly. C.M.K. declares no competing interests.
Figures
